S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
NYSE:MDT

Medtronic (MDT) Stock Forecast, Price & News

$102.75
-0.82 (-0.79%)
(As of 05/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$101.25
$103.25
50-Day Range
$99.58
$113.09
52-Week Range
$98.38
$135.89
Volume
4.18 million shs
Average Volume
4.85 million shs
Market Capitalization
$137.84 billion
P/E Ratio
28.31
Dividend Yield
2.43%
Beta
0.74
30 days | 90 days | 365 days | Advanced Chart
Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for Medtronic and its competitors with MarketBeat's FREE daily newsletter.

Medtronic logo

About Medtronic

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Headlines

Highly Valued Abbot Laboratories Could Move Lower (MDT)
Abbott Laboratories (NYSE: ABT) is not in danger of losing its business but we have some concerns its share price could fall. Not only is it a highly-valued stock compared to peers but its current revenue and earnings are based largely on COVID-19.
Medtronic completes acquisition of Intersect ENT
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
58505510
Employees
90,000
Year Founded
1949

Sales & Book Value

Annual Sales
$30.12 billion
Cash Flow
$4.66 per share
Book Value
$38.28 per share

Profitability

Net Income
$3.61 billion
Pretax Margin
17.24%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
1,341,540,000
Free Float
1,335,234,000
Market Cap
$137.84 billion
Optionable
Optionable

Company Calendar

Last Earnings
2/22/2022
Ex-Dividend for 4/22 Dividend
3/24/2022
Dividend Payable
4/22/2022
Today
5/19/2022
Next Earnings (Confirmed)
5/26/2022
Fiscal Year End
4/30/2023

Social Links


MarketRank

Overall MarketRank

3.11 out of 5 stars

Medical Sector

11th out of 1,418 stocks

Electromedical Equipment Industry

1st out of 29 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 4.2Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Medtronic (NYSE:MDT) Frequently Asked Questions

Is Medtronic a buy right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There are currently 10 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medtronic stock.
View analyst ratings for Medtronic
or view top-rated stocks.

When is Medtronic's next earnings date?

Medtronic is scheduled to release its next quarterly earnings announcement on Thursday, May 26th 2022.
View our earnings forecast for Medtronic
.

How can I listen to Medtronic's earnings call?

Medtronic will be holding an earnings conference call on Thursday, May 26th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Medtronic's earnings last quarter?

Medtronic plc (NYSE:MDT) issued its quarterly earnings results on Tuesday, February, 22nd. The medical technology company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.01. The medical technology company earned $7.76 billion during the quarter, compared to the consensus estimate of $7.91 billion. Medtronic had a net margin of 15.46% and a trailing twelve-month return on equity of 14.57%. The business's revenue was down .2% on a year-over-year basis. During the same period in the previous year, the business posted $1.29 earnings per share.
View Medtronic's earnings history
.

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Friday, March 4th. Stockholders of record on Friday, March 25th will be given a dividend of $0.63 per share on Friday, April 22nd. This represents a $2.52 annualized dividend and a dividend yield of 2.45%. The ex-dividend date of this dividend is Thursday, March 24th.
View Medtronic's dividend history
.

Is Medtronic a good dividend stock?

Medtronic pays an annual dividend of $2.52 per share and currently has a dividend yield of 2.37%. Medtronic has been increasing its dividend for 45 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Medtronic is 69.42%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medtronic will have a dividend payout ratio of 43.37% next year. This indicates that Medtronic will be able to sustain or increase its dividend.
View Medtronic's dividend history.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic issued an update on its fourth quarter 2022 earnings guidance on Tuesday, March, 15th. The company provided EPS guidance of $1.560-$1.580 for the period, compared to the consensus estimate of $1.580. The company issued revenue guidance of -.

What price target have analysts set for MDT?

21 equities research analysts have issued twelve-month target prices for Medtronic's stock. Their forecasts range from $104.00 to $165.00. On average, they expect Medtronic's stock price to reach $127.32 in the next year. This suggests a possible upside of 23.9% from the stock's current price.
View analysts' price targets for Medtronic
or view top-rated stocks among Wall Street analysts.

Who are Medtronic's key executives?
Medtronic's management team includes the following people:
  • Mr. Geoffrey Straub Martha, Chairman & CEO (Age 52, Pay $4.09M)
  • Ms. Karen L. Parkhill, EVP, CFO, IT & Enterprise Excellence (Age 57, Pay $3.29M) (LinkedIn Profile)
  • Dr. Richard E. Kuntz M.D., M.Sc., Sr. VP and Chief Medical & Scientific Officer (Age 65, Pay $2.61M)
  • Mr. Robert John White, Exec. VP & Pres of Medical Surgical Portfolio (Age 59, Pay $2.66M) (LinkedIn Profile)
  • Mr. Mark Ploof, Sr. VP of Global Operations and Bus. Services
  • Ms. Jennifer M. Kirk, Principal Accounting Officer, Global Controller & Chief Accounting Officer (Age 47)
  • Mr. Sean Lennon, Chief Information Officer
  • Mr. Ryan Weispfenning, VP of Investor Relations
  • Mr. Ivan K. Fong, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Torod B. Neptune, Sr. VP & Chief Communications Officer
What is Omar S. Ishrak's approval rating as Medtronic's CEO?

1,925 employees have rated Medtronic CEO Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among Medtronic's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and Walmart (WMT).

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.99%), BlackRock Inc. (8.05%), State Street Corp (4.36%), Massachusetts Financial Services Co. MA (3.08%), Wellington Management Group LLP (2.32%) and Lazard Asset Management LLC (1.64%). Company insiders that own Medtronic stock include Bradley E Lerman, Brett A Wall, Brett A Wall, Carol A Surface, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, John R Liddicoat, Karen L Parkhill, Karen L Parkhill, Omar Ishrak, Richard H Anderson, Richard H Anderson, Robert John White and Sean Salmon.
View institutional ownership trends for Medtronic
.

Which major investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Lazard Asset Management LLC, Clearbridge Investments LLC, Cibc World Markets Corp, Canada Pension Plan Investment Board, Healthcare of Ontario Pension Plan Trust Fund, Bank of Montreal Can, and Bahl & Gaynor Inc.. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Brett A Wall, Carol A Surface, Geoffrey Martha, John R Liddicoat, Karen L Parkhill, Robert John White, and Sean Salmon.
View insider buying and selling activity for Medtronic
or view top insider-selling stocks.

Which major investors are buying Medtronic stock?

MDT stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sumitomo Mitsui Trust Holdings Inc., Invesco Ltd., Bridgewater Associates LP, SG Americas Securities LLC, Capital Research Global Investors, Aaron Wealth Advisors LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Medtronic
or or view top insider-buying stocks.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $102.75.

How much money does Medtronic make?

Medtronic has a market capitalization of $137.84 billion and generates $30.12 billion in revenue each year. The medical technology company earns $3.61 billion in net income (profit) each year or $3.63 on an earnings per share basis.

How many employees does Medtronic have?

Medtronic employs 90,000 workers across the globe.

When was Medtronic founded?

Medtronic was founded in 1949.

What is Medtronic's official website?

The official website for Medtronic is www.medtronic.com.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at (531) 438-1700, via email at [email protected], or via fax at 763-514-4879.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.